AbbVie, Momenta Settle To Delay Sixth Humira Biosimilar

November 09, 2018
AbbVie reached its sixth settlement to delay release of a biosimilar version of its blockbuster arthritis drug Humira, which is the bestselling prescription drug in the world. The manufacturer announced its deal with Momenta on Tuesday, two days before potential incoming Senate Finance Committee chair Sen. Chuck Grassley (R-IA) co-authored a letter asking the president to endorse a bill banning such settlements. Under the agreement, Momenta will not be allowed to release its Humira biosimilar in the United States until...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.